Preferred Label : Anti-PD-L1/Anti-TIGIT Bispecific Antibody PM1022;
NCIt synonyms : Anti-TIGIT/PD-L1 Bispecific Antibody PM1022; Anti-PD-L1/TIGIT Bispecific Antibody PM1022; TIGIT x PD-L1 Bispecific Antibody PM1022; PD-L1 x TIGIT Bispecific Antibody PM 1022; Anti-TIGIT/Anti-PD-L1 Bispecific Antibody PM1022;
NCIt definition : A recombinant humanized bispecific antibody directed against both the co-inhibitory
molecule and immune checkpoint inhibitor T-cell immunoreceptor with immunoglobulin
(Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM) domains (TIGIT) and
the immunosuppressive ligand programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation
274; CD274), with potential immune checkpoint inhibitory and antineoplastic activities.
Upon administration, anti-TIGIT/anti-PD-L1 bispecific antibody PM1022 simultaneously
targets, binds to and inhibits TIGIT and PD-L1, thereby inhibiting their downstream
signaling pathways. Inhibition of TIGIT, which is expressed on various immune cells
and particularly on tumor-infiltrating lymphocytes (TILs), prevents the interaction
of TIGIT with its ligands CD112 (nectin-2; poliovirus receptor related-2; PRR2; PVRL2)
and CD155 (poliovirus receptor; PVR; nectin-like protein 5; NECL-5). This enhances
the interaction of CD112 and CD155 with the costimulatory receptor CD226 (DNAX Accessory
molecule-1; DNAM-1), which is expressed on immune cells, such as natural killer (NK)
cells and CD8 T-cells. This leads to CD226 dimerization and CD226-mediated signaling
and activates the immune system to exert a T-cell-mediated immune response against
cancer cells. Inhibition of PD-L1 prevents its binding to and activation of its receptor,
programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This abrogates T-cell
inhibition, activates antigen-specific T-lymphocytes and enhances cytotoxic T-cell-mediated
tumor cell lysis, which may lead to a reduction in tumor growth. TIGIT, a member of
the Ig super family (IgSF) and an immune inhibitory receptor, plays a key role in
the suppression of T-cell proliferation and activation; it is involved in tumor cell
immune evasion. PD-L1 binding to PD-1 on activated T-cells inhibits the expansion
and survival of CD8-positive T-cells, suppresses the immune system and results in
immune evasion.;
Molecule name : PM 1022; PM-1022;
NCI Metathesaurus CUI : CL1915086;
Origin ID : C200806;
UMLS CUI : C5854594;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
